Panbela Therapeutics Has Been Granted European Patent Number EP3746425 Titled "Methods For Producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol (The Company's Lead Investigational Product Sbp-101 For The Treatment Of Metastatic Pancreatic Cancer)"
Portfolio Pulse from Happy Mohamed
Panbela Therapeutics has been granted European Patent Number EP3746425 for its lead investigational product SBP-101, used for the treatment of metastatic pancreatic cancer.
June 30, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The granting of the European patent for Panbela's lead investigational product SBP-101 could potentially increase the company's market reach and protect its intellectual property rights in Europe.
The granting of a patent is a significant milestone for biotech companies as it provides protection for their intellectual property, potentially leading to increased market reach and revenue. This could positively impact Panbela's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100